Related Experiment Video
Updated: May 29, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
Identification of a novel Mcl-1 protein binding motif
William J Placzek1, Mattia Sturlese, Bainan Wu
1Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA.
Abstract:
Recent characterization of Mcl-1 as the primary anti-apoptotic Bcl-2 family member expressed in solid tumors, coupled with its ability to enable therapeutic resistance, has provided the impetus for further study into how Mcl-1 is involved in apoptosis signaling. Here, we employ Sabutoclax, a potent and effective Mcl-1 antagonist, as a competing agent to screen a randomized 12-residue phage display library for peptides that bind strongly to the Bcl-2 homology 3 (BH3) binding groove of Mcl-1. Although the screen identified a number of α-helical peptides with canonical BH3 domain sequences, it also isolated a pair of unique peptide sequences. These sequences exhibit a reverse organization of conserved hydrophobic and acidic residues when compared with canonical BH3 sequences, and we therefore refer to them as reverse BH3 (rBH3) peptides. Furthermore, studies of the rBH3 peptides using NMR spectroscopy, fluorescence polarization displacement assays, and alanine scanning data all suggest that they bind to the BH3 binding groove of Mcl-1 selectively over Bcl-x(L). A search for proteins containing the rBH3 motif has identified a number of interesting Mcl-1 protein partners, some of which have previously been associated with apoptosis regulation involving Mcl-1. These findings provide insights into the development of more specific Mcl-1 antagonists and open the way to the identification of a previously unknown family of apoptosis-regulating and Mcl-1 interacting proteins.
Insights
Researchers identified novel reverse BH3 (rBH3) peptides that selectively bind to Mcl-1, a key protein in cancer therapeutic resistance. These rBH3 peptides offer potential for developing more specific Mcl-1 antagonists and discovering new apoptosis regulators.
Area of Science:
- Molecular Biology
- Biochemistry
- Cancer Research
Background:
- Mcl-1 is a primary anti-apoptotic protein in solid tumors, contributing to therapeutic resistance.
- Understanding Mcl-1's role in apoptosis signaling is crucial for developing new cancer therapies.
Purpose of the Study:
- To screen for peptides that bind to the Mcl-1's Bcl-2 homology 3 (BH3) binding groove.
- To identify novel Mcl-1 antagonists and understand their binding mechanisms.
Main Methods:
- Utilized Sabutoclax, an Mcl-1 antagonist, to screen a phage display library for binding peptides.
- Employed NMR spectroscopy, fluorescence polarization displacement assays, and alanine scanning to characterize peptide binding.
- Searched for proteins containing the identified reverse BH3 (rBH3) motif.
Main Results:
- Identified canonical BH3 domain peptides and unique reverse BH3 (rBH3) peptides.
- rBH3 peptides exhibit a reversed organization of hydrophobic and acidic residues compared to canonical BH3 sequences.
- rBH3 peptides selectively bind to Mcl-1's BH3 binding groove over Bcl-x(L).
- Discovered novel Mcl-1 protein partners, some linked to apoptosis regulation.
Conclusions:
- rBH3 peptides represent a novel class of Mcl-1 binders.
- These findings facilitate the development of specific Mcl-1 antagonists.
- Opens avenues for identifying new Mcl-1 interacting proteins involved in apoptosis regulation.

